Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of QX005N in Chinese patients with moderate-to-severe atopic dermatitis
CTR20241068Phase 3Active
- Sponsor
- Qiansin
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QX005N in atopic dermatitis (AD), sponsored by Qiansin. Started May 2024; status: active.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241068.